Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Rangaraj Selvarangan and Dithi Banerjee.
|
|
Connection Strength |
|
![](https://researchers.childrensmercy.org/Framework/Images/connection_left.gif) |
|
![](https://researchers.childrensmercy.org/Framework/Images/connection_right.gif) |
|
5.334 |
|
|
|
-
Banerjee D, Hassan F, Avadhanula V, Piedra PA, Boom J, Sahni LC, Weinberg GA, Lindstrom S, Rha B, Harrison CJ, Selvarangan R. Comparative analysis of three multiplex platforms for the detection of respiratory viral pathogens. J Clin Virol. 2022 11; 156:105274.
Score: 0.882
-
Banerjee D, Sasidharan A, Abdulhamid A, Orosco EM, Watts JL, Schuster JE, Myers AL, Weddle G, Selvarangan R. Diagnostic Yield of Saliva for SARS-CoV-2 Molecular Testing in Children. J Pediatric Infect Dis Soc. 2021 Nov 11; 10(10):967-969.
Score: 0.835
-
Banerjee D, Michael J, Schmitt B, Salimnia H, Mhaissen N, Goldfarb DM, Lachance P, Faron ML, Aufderheide T, Ledeboer N, Weissfeld A, Selvarangan R. Multicenter Clinical Evaluation of the Revogene Strep A Molecular Assay for Detection of Streptococcus pyogenes from Throat Swab Specimens. J Clin Microbiol. 2020 06 24; 58(7).
Score: 0.758
-
Banerjee D, Kanwar N, Hassan F, Lankachandra K, Selvarangan R. Comparative analysis of Four sample-to-answer influenza A/B and RSV nucleic acid amplification assays using adult respiratory specimens. J Clin Virol. 2019 09; 118:9-13.
Score: 0.709
-
Banerjee D, Kanwar N, Hassan F, Essmyer C, Selvarangan R. Comparison of Six Sample-to-Answer Influenza A/B and Respiratory Syncytial Virus Nucleic Acid Amplification Assays Using Respiratory Specimens from Children. J Clin Microbiol. 2018 11; 56(11).
Score: 0.676
-
Gummersheimer S, Hayes A, Harrison C, Lee B, Schuster J, Dhar M, Sasidharan A, Banerjee D, Selvarangan R. Prevalence and clinical presentation of EV-D68 infections in Kansas City children during the 2022 season. Diagn Microbiol Infect Dis. 2023 Sep; 107(1):115992.
Score: 0.232
-
Sasidharan A, Banerjee D, Harrison CJ, Selvarangan R. Emergence of Parechovirus A3 as the Leading Cause of Central Nervous System Infection, Surpassing Any Single Enterovirus Type, in Children in Kansas City, Missouri, USA, from 2007 to 2016. J Clin Microbiol. 2021 05 19; 59(6).
Score: 0.202
-
Kanwar N, Banerjee D, Harrison CJ, Newland JG, Qin X, Zerr DM, Zaoutis T, Selvarangan R. Comparative in?vitro effectiveness of ceftolozane/tazobactam against pediatric gram-negative drug-resistant isolates. J Chemother. 2021 Sep; 33(5):288-293.
Score: 0.199
-
Schuster JE, Banerjee D, Ahmed I, Selvarangan R. Frequency of asymptomatic and symptomatic respiratory virus detection in pediatric hematopoietic cell transplant patients. Pediatr Transplant. 2020 09; 24(6):e13732.
Score: 0.188
-
Sasidharan A, Harrison CJ, Banerjee D, Selvarangan R. Emergence of Parechovirus A4 Central Nervous System Infections among Infants in Kansas City, Missouri, USA. J Clin Microbiol. 2019 05; 57(5).
Score: 0.175
-
Moline HL, Tannis A, Toepfer AP, Williams JV, Boom JA, Englund JA, Halasa NB, Staat MA, Weinberg GA, Selvarangan R, Michaels MG, Sahni LC, Klein EJ, Stewart LS, Schlaudecker EP, Szilagyi PG, Schuster JE, Goldstein L, Musa S, Piedra PA, Zerr DM, Betters KA, Rohlfs C, Albertin C, Banerjee D, McKeever ER, Kalman C, Clopper BR, McMorrow ML, Dawood FS. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024 Mar 07; 73(9):209-214.
Score: 0.061
-
Gross R, Thaweethai T, Rosenzweig EB, Chan J, Chibnik LB, Cicek MS, Elliott AJ, Flaherman VJ, Foulkes AS, Witvliet MG, Gallagher R, Gennaro ML, Jernigan TL, Karlson EW, Katz SD, Kinser PA, Kleinman LC, Lamendola-Essel MF, Milner JD, Mohandas S, Mudumbi PC, Newburger JW, Rhee KE, Salisbury AL, Snowden JN, Stein CR, Stockwell MS, Tantisira KG, Thomason ME, Truong DT, Warburton D, Wood JC, Ahmed S, Akerlundh A, Alshawabkeh AN, Anderson BR, Aschner JL, Atz AM, Aupperle RL, Baker FC, Balaraman V, Banerjee D, Barch DM, Baskin-Sommers A, Bhuiyan S, Bind MC, Bogie AL, Buchbinder NC, Bueler E, B?k?lmez H, Casey BJ, Chang L, Clark DB, Clifton RG, Clouser KN, Cottrell L, Cowan K, D'Sa V, Dapretto M, Dasgupta S, Dehority W, Dummer KB, Elias MD, Esquenazi-Karonika S, Evans DN, Faustino EVS, Fiks AG, Forsha D, Foxe JJ, Friedman NP, Fry G, Gaur S, Gee DG, Gray KM, Harahsheh AS, Heath AC, Heitzeg MM, Hester CM, Hill S, Hobart-Porter L, Hong TKF, Horowitz CR, Hsia DS, Huentelman M, Hummel KD, Iacono WG, Irby K, Jacobus J, Jacoby VL, Jone PN, Kaelber DC, Kasmarcak TJ, Kluko MJ, Kosut JS, Laird AR, Landeo-Gutierrez J, Lang SM, Larson CL, Lim PPC, Lisdahl KM, McCrindle BW, McCulloh RJ, Mendelsohn AL, Metz TD, Morgan LM, M?ller-Oehring EM, Nahin ER, Neale MC, Ness-Cochinwala M, Nolan SM, Oliveira CR, Oster ME, Payne RM, Raissy H, Randall IG, Rao S, Reeder HT, Rosas JM, Russell MW, Sabati AA, Sanil Y, Sato AI, Schechter MS, Selvarangan R, Shakti D, Sharma K, Squeglia LM, Stevenson MD, Szmuszkovicz J, Talavera-Barber MM, Teufel RJ, Thacker D, Udosen MM, Warner MR, Watson SE, Werzberger A, Weyer JC, Wood MJ, Yin HS, Zempsky WT, Zimmerman E, Dreyer BP. Researching COVID to enhance recovery (RECOVER) pediatric study protocol: Rationale, objectives and design. medRxiv. 2023 May 12.
Score: 0.058
-
Fraley E, LeMaster C, Khanal S, Banerjee D, Pastinen T, Grundberg E, Selvarangan R, Bradley T. The Impact of Prior Infection and Age on Antibody Persistence After Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine. Clin Infect Dis. 2022 08 24; 75(1):e902-e904.
Score: 0.055
-
Kanwar N, Banerjee D, Sasidharan A, Abdulhamid A, Larson M, Lee B, Selvarangan R, Liesman RM. Comparison of diagnostic performance of five molecular assays for detection of SARS-CoV-2. Diagn Microbiol Infect Dis. 2021 Dec; 101(4):115518.
Score: 0.051
-
Winkley K, Banerjee D, Bradley T, Koseva B, Cheung WA, Selvarangan R, Pastinen T, Grundberg E. Immune cell residency in the nasal mucosa may partially explain respiratory disease severity across the age range. Sci Rep. 2021 08 05; 11(1):15927.
Score: 0.051
-
Fraley E, LeMaster C, Geanes E, Banerjee D, Khanal S, Grundberg E, Selvarangan R, Bradley T. Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals. BMC Med. 2021 07 26; 19(1):169.
Score: 0.051
-
Fraley E, LeMaster C, Banerjee D, Khanal S, Selvarangan R, Bradley T. Cross-reactive antibody immunity against SARS-CoV-2 in children and adults. Cell Mol Immunol. 2021 07; 18(7):1826-1828.
Score: 0.051
-
Bradley T, Grundberg E, Selvarangan R, LeMaster C, Fraley E, Banerjee D, Belden B, Louiselle D, Nolte N, Biswell R, Pastinen T, Myers A, Schuster J. Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med. 2021 05 20; 384(20):1959-1961.
Score: 0.050
-
Winkley K, Koseva B, Banerjee D, Cheung W, Selvarangan R, Pastinen T, Grundberg E. High-resolution epigenome analysis in nasal samples derived from children with respiratory viral infections reveals striking changes upon SARS-CoV-2 infection. medRxiv. 2021 Mar 11.
Score: 0.050
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|